Search

Your search keyword '"VISCERAL leishmaniasis"' showing total 3,179 results

Search Constraints

Start Over You searched for: Descriptor "VISCERAL leishmaniasis" Remove constraint Descriptor: "VISCERAL leishmaniasis" Search Limiters Academic (Peer-Reviewed) Journals Remove constraint Search Limiters: Academic (Peer-Reviewed) Journals Topic leishmania infantum Remove constraint Topic: leishmania infantum
3,179 results on '"VISCERAL leishmaniasis"'

Search Results

1. Effect of Leishmania infantum infection on B cell lymphopoiesis and memory in the bone marrow and spleen.

2. Concanavalin A, lectin from Canavalia ensiformis seeds has Leishmania infantum antipromastigote activity mediated by carbohydrate recognition domain.

3. Genomic and epidemiological evidence for the emergence of a L. infantum/L. donovani hybrid with unusual epidemiology in northern Italy.

4. Nicotinamide mitigates visceral leishmaniasis by regulating inflammatory response and enhancing lipid metabolism.

5. Leishmania infantum detection in Nyssomyia neivai and dogs in Southern Brazil.

6. Immunotherapy Combining Mimotopes Selected by Phage Display Plus Amphotericin B Is Effective for Treatment Against Visceral Leishmaniasis.

7. Leishmania and HIV co-infection: first naturally Leishmania strain presenting decreased susceptibility to miltefosine, recovered from a patient in Portugal.

8. Intranasal delivery of LaAg vaccine improves immunity of aged mice against visceral Leishmaniasis.

9. Recognition of Immunoreactive Proteins in Leishmania infantum Amastigote-Like and Promastigote Using Sera of Visceral Leishmaniasis Patients: a Preliminary Study.

10. Understanding hypergammaglobulinemia in experimental or natural visceral leishmaniasis.

11. Re-emergence of human leishmaniasis in northern Italy, 2004 to 2022: a retrospective analysis.

12. Immunosuppressants alter the immune response associated with Glucantime ® treatment for Leishmania infantum infection in a mouse model.

13. Evolving immunometabolic response to the early Leishmania infantum infection in the spleen of BALB/c mice described by gene expression profiling.

14. Anorexia, lethargy, weakness, and acute respiratory distress in a 5-year-old male intact mixed-breed dog.

15. Elucidating the role played by bone marrow in visceral leishmaniasis.

16. Antileishmanial activity of 2-amino-thiophene derivative SB-200.

17. Molecular Detection of Leishmania in Wild Caught Sand Flies of Larroussius Subgenus in Iran: Combined Use of Internal and External Morphological Characters as a Mean to Differentiate Morphologically Similar Females.

18. Visceral Leishmaniasis Caused by Leishmania Tropica.

19. Recombinant endonuclease III protein from Leishmania infantum associated with Th1-type adjuvants is immunogenic and induces protection against visceral leishmaniasis.

20. Exploring the repositioning of the amodiaquine as potential drug against visceral leishmaniasis: The in vitro effect against Leishmania infantum is associated with multiple mechanisms, involving mitochondria dysfunction, oxidative stress and loss of cell cycle control.

21. Leishmania infantum (syn. Leishmania chagasi) detection in blood donors living in an endemic area.

22. Leishmania infantum infecting the carnivore Nasua nasua from urban forest fragments in an endemic area of visceral leishmaniasis in Brazilian Midwest.

23. Parasite Genotype Is a Major Predictor of Mortality from Visceral Leishmaniasis.

24. Factors associated with Leishmania infantum infection in dogs from urban areas endemic for visceral leishmaniasis in Brazil.

25. 3'Nucleotidase/nuclease is required for Leishmania infantum clinical isolate susceptibility to miltefosine.

26. Use of N-acetylcysteine as treatment adjuvant regulates immune response in visceral leishmaniasis: Pilot clinical trial and in vitro experiments.

27. Leishmania infantum reactivation with secondary IgA nephropathy.

28. High seroprevalence of Leishmania infantum infection in dogs and its associated risk factors in selected towns of Southwest and West Shewa zones of Oromia, Ethiopia.

29. A new immunochemotherapy schedule for visceral leishmaniasis in a hamster model.

30. A specific Leishmania infantum polyepitope vaccine triggers Th1-type immune response and protects against experimental visceral leishmaniasis.

31. MIS-C and Visceral Leishmaniasis Co-occurence: Has the Clinic of Other Diseases Masked in the Pandemia?

32. Immunotherapy for visceral leishmaniasis: A trapeze of balancing counteractive forces.

33. The repellency effect of icaridin nanostructural solution applied on cotton knitting fabric against Lutzomyia longipalpis.

34. [Epidemiological investigation on a visceral leishmaniasis case in Zhengzhou City of Henan Province].

35. Ageing impairs protective immunity and promotes susceptibility to murine visceral leishmaniasis.

36. A structural vaccinology approach for in silico designing of a potential self-assembled nanovaccine against Leishmania infantum.

37. Leishmania LiHyC protein is immunogenic and induces protection against visceral leishmaniasis.

38. Evaluation of prime and prime-boost immunization strategies in BALB/c mice inoculated with Leishmania infantum transfected with toxic plasmids.

39. Xenodiagnosis in four domestic cats naturally infected by Leishmania infantum.

40. Parasitological and immunological evaluation of a quinoline derivative salt incorporated into a polymeric micelle formulation against Leishmania infantum infection.

41. First report of imported canine visceral leishmaniasis cases in Panama, Central America: Public health implications.

42. Multiplex qPCR assay to determine Leishmania infantum load in Lutzomyia longipalpis sandfly samples.

43. A recombinant Leishmania amastigote-specific protein, rLiHyG, with adjuvants, protects against infection with Leishmania infantum.

44. Recombinant guanosine-5'-triphosphate (GTP)-binding protein associated with Poloxamer 407-based polymeric micelles protects against Leishmania infantum infection.

45. Intranasal immunization with chitosan microparticles enhances LACK-DNA vaccine protection and induces specific long-lasting immunity against visceral leishmaniasis.

46. Immunochemotherapy for visceral leishmaniasis: combinatorial action of Miltefosine plus LBSapMPL vaccine improves adaptative Th1 immune response with control of splenic parasitism in experimental hamster model.

47. miR-548d-3p Is Up-Regulated in Human Visceral Leishmaniasis and Suppresses Parasite Growth in Macrophages.

48. Flau-A, a naphthoquinone derivative, is a promising therapeutic candidate against visceral leishmaniasis: A preliminary study.

49. Amplicon-based next-generation sequencing reveals the co-existence of multiple Leishmania species in patients with visceral leishmaniasis.

50. Protective immune response mediated by neutrophils in experimental visceral leishmaniasis is enhanced by IL-32γ.

Catalog

Books, media, physical & digital resources